Germany-based Evotec SE (NASDAQ:EVO) is trading on Monday after a report that suggests the company is a takeover target. The ...

Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance ...

News of the offer arrived days after Bloomberg reported that the private equity group Triton Partners, which has built an ...

Update 1:50pm: Updates shares, adds further details. Evotec SE (NASDAQ:EVO) ADRs surged 18% after a report that Triton Partners is considering a takeover offer for the German drug developer. Triton is ...

Halozyme Therapeutics (HALO) offered to acquire German drug maker Evotec (EVO) in a deal with an equity value of 2 billion euros ($2.11 billion). Halozyme submitted a non-binding proposal to Evotec's ...

Evotec’s struggles have put it in the crosshairs of private equity groups. After seeing the company’s share price fall around ...

Evotec surged on Friday after Halozyme Therapeutics confirmed it had submitted a non-binding proposal to buy the German ...

Triton Partners is considering a takeover bid for Germany’s Evotec SE, according to people familiar with the matter, after the private equity firm emerged as one of the drug developer’s ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to ...

Halozyme Therapeutics Inc. (HALO) confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of ...

Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) ...

The private equity firm Triton Partners is reportedly considering acquiring Evotec, Bloomberg reported, citing people familiar with the matter. In an SEC filing, Evotec reported that Triton had ...